
Morgan Stanley analyst Sean Laaman lowered the firm’s price target on Immunocore (IMCR) to $42 from $43 and keeps an Equal Weight rating on the shares. The firm adjusted estimates
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| IMCR | Immunocore Holdings | 26.41 | -12.94 | -32.88% |
| Name | Price | % Change | |
|---|---|---|---|
| $26.41 | -32.88% |

Morgan Stanley analyst Sean Laaman lowered the firm’s price target on Immunocore (IMCR) to $42 from $43 and keeps an Equal Weight rating on the shares. The firm adjusted estimates

H.C. Wainwright lowered the firm’s price target on Immunocore (IMCR) to $80 from $100 and keeps a Buy rating on the shares following the Q3 report. The firm cites later

Immunocore Holdings Plc (IMCR) is scheduled to report 3rd quarter earnings on 11/11/2026. Regarding Q3 estimates, Wall Street analysts expect Immunocore Holdings Plc to post earnings of -$0.13 per share.

Immunocore (IMCR) Holdings presented data from its Phase 1/2 trial evaluating brenetafusp alone and in combination with KIMMTRAK in HLA-A*02:01-positive patients with metastatic uveal melanoma, in a poster session at

Reports Q3 revenue $102.22M, consensus $113.36M. “Nearly five years after launch, KIMMTRAK remains the proven standard of care in HLA-A 02:01+ metastatic uveal melanoma. With TEBE-AM fully enrolled and data

Immunocore Holdings Plc ($IMCR) announced an update on their ongoing clinical study. Immunocore Holdings Plc (IMCR) has updated results from its Phase II study named “A Phase II Randomized, Open-label,

Mizuho lowered the firm’s price target on Immunocore (IMCR) to $33 from $35 and keeps a Neutral rating on the shares. Published first on TheFly – the ultimate source for

Immunocore Holdings, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on the stock and has a

Immunocore (IMCR) announced that the first patient with type 1 diabetes, or T1D, has been dosed in the Phase 1 trial of IMC-S118AI. The Phase 1 dose escalation trial will

An announcement from Immunocore Holdings ( ($IMCR) ) is now available. On September 14, 2026, Immunocore announced it had reached target enrollment of 540 patients in its global, randomized Phase
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| hold | Assigned | Nov 13, 2026 | ||||
| buy | Reiterated | Nov 12, 2026 | ||||
| buy | Reiterated | Nov 10, 2026 | ||||
| hold | Reiterated | Oct 29, 2026 | ||||
| buy | Initiated | Aug 21, 2026 | ||||
| buy | Reiterated | Aug 6, 2026 | ||||
| buy | Reiterated | May 6, 2026 | ||||
| buy | Reiterated | Apr 14, 2026 | ||||
| hold | Downgraded | Mar 15, 2026 | ||||
| buy | Initiated | Jan 6, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 3, 2027TBA | $1.36B | $-0.20 | $112.23M | 1.62 | -41.73 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.